Company profile
Aurealis Therapeutics company profile
They exist to develop curative solutions that achieve total and faster healing for non-healing wounds and other complex inflammatory diseases with their four-in-one biologic drug, AUP-16. Their goal is to create solid Phase 2 clinical efficacy data in diabetic foot ulcers and non-clinical proof-of-concept data in other inflammatory diseases by end of 2022, and to engage with strategic partners to ensure that this game changing technology benefits millions of patients.
Business identity
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00011-00050 employees
- Revenue range
- $1K+
- Founded
- 2015-01-01
Headquarters
- Headquarters
- Kuopio, North Savo, Finland
- Postal code
- 70210
- Country code
- FI
- Continent
- Europe